Cancers 2013, 5(3), 838-856; doi:10.3390/cancers5030838
Review

HEXIM1, a New Player in the p53 Pathway

1, 1, 1, 1 and 1,2,* email
Received: 27 May 2013; in revised form: 24 June 2013 / Accepted: 24 June 2013 / Published: 4 July 2013
(This article belongs to the Special Issue The p53 Pathway in Cancers)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Hexamethylene bisacetamide-inducible protein 1 (HEXIM1) is best known as the inhibitor of positive transcription elongation factor b (P-TEFb), which controls transcription elongation of RNA polymerase II and Tat transactivation of human immunodeficiency virus. Besides P-TEFb, several proteins have been identified as HEXIM1 binding proteins. It is noteworthy that more than half of the HEXIM1 binding partners are involved in cancers. P53 and two key regulators of the p53 pathway, nucleophosmin (NPM) and human double minute-2 protein (HDM2), are among the factors identified. This review will focus on the functional importance of the interactions between HEXIM1 and p53/NPM/HDM2. NPM and the cytoplasmic mutant of NPM, NPMc+, were found to regulate P-TEFb activity and RNA polymerase II transcription through the interaction with HEXIM1. Importantly, more than one-third of acute myeloid leukemia (AML) patients carry NPMc+, suggesting the involvement of HEXIM1 in tumorigenesis of AML. HDM2 was found to ubiquitinate HEXIM1. The HDM2-mediated ubiquitination of HEXIM1 did not lead to protein degradation of HEXIM1 but enhanced its inhibitory activity on P-TEFb. Recently, HEXIM1 was identified as a novel positive regulator of p53. HEXIM1 prevented p53 ubiquitination by competing with HDM2 in binding to p53. Taken together, the new evidence suggests a role of HEXIM1 in regulating the p53 pathway and tumorigenesis.
Keywords: HEXIM1; P-TEFb; p53; HDM2; NPM; NPMc+
PDF Full-text Download PDF Full-Text [931 KB, uploaded 4 July 2013 17:37 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Lew, Q.J.; Chu, K.L.; Chia, Y.L.; Cheong, N.; Chao, S.-H. HEXIM1, a New Player in the p53 Pathway. Cancers 2013, 5, 838-856.

AMA Style

Lew QJ, Chu KL, Chia YL, Cheong N, Chao S-H. HEXIM1, a New Player in the p53 Pathway. Cancers. 2013; 5(3):838-856.

Chicago/Turabian Style

Lew, Qiao J.; Chu, Kai L.; Chia, Yi L.; Cheong, Nge; Chao, Sheng-Hao. 2013. "HEXIM1, a New Player in the p53 Pathway." Cancers 5, no. 3: 838-856.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert